This is an expanded access program (EAP) for eligible participants designed to provideaccess to CC-486.
Drug: CC-486
Oral azacitidine administered as directed by treating physician.
Other Name: Oral Azacitidine
Inclusion Criteria:
-Adult patients with documented acute myelogenous leukemia (AML) in their first complete
remission (CR) or complete remission with incomplete blood count recovery (CRi) following
induction therapy with or without consolidation treatment, who seek treatment with CC-486
as monotherapy to maintain their CR or CRi.
Exclusion Criteria:
- Patients with AML in CR/CRi who plan to proceed to or are waiting for a bone marrow
transplant
- Patients who have received a bone marrow transplant for the treatment of AML
- Treatment of AML patients with relapse or refractory disease
- Pregnant or breast-feeding females
- Patient meets enrollment criteria and can participate in a disease-specific clinical
trial
Celgene
Summit, New Jersey, United States